In this podcast, hear from Prof Hartmut Döhner, Hematologist-Oncologist and Professor of Medicine in Germany, as he discusses the growing roles of precise treatments based on the characteristics of the leukemic cells in acute myeloid leukemias. Discover the clinical developments of targeted treatments such as IDH1/2 inhibitors and venetoclax, and learn about the importance of combination treatment to improve results.
The podcast also explores the use of epigenetic agents as part of standard care in older patients and how the proportion of patients treated with targeted agents is increasing. Tune in to find out how more AML patients may benefit from precision medicine and targeted therapy.
The podcast is based on the paper: "Towards precision medicine for AML", by Döhner H, et al. Nat Rev Clin Oncol. 2021;18:577-590. (https://pubmed.ncbi.nlm.nih.gov/34006997/)
Host: Dr Nathalie van Havre; Guest: Prof Hartmut Döhner
Learn More
To learn more about AML and updated classification and prognostic recommendations, check out QR Case 19 on AML on the EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe